purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation ino earnings call period ending december image source motley fool inovio pharmaceutical ino q earnings callmar pm etcontents prepared remark question answer call participant prepared remark operatorgood afternoon lady gentleman welcome inovio fourthquarter yearend financial result conference call time line listenonly mode following presentation conduct questionandanswer session operator instruction call recorded wednesday march th would like turn conference thomas hong manager investor relation please go aheadthomas hong investor relation manager good afternoon thank joining inovio fourthquarter fullyear financial result conference call joining today call dr jackie shea president chief executive officer dr michael sumner chief medical officer mark twyman chief commercial officer peter ky chief financial officer today call review corporate financial information quarter full year ended december st well provide general business update following prepared remark conduct questionandanswer segment call making forwardlooking statement regarding future event future performance company event relate business plan develop inovios dna medicine platform include clinical regulatory development timing clinical data readout along capital resource strategic matter statement based belief expectation management todayactual event result could differ materially refer document file time time sec heading risk factor identify important factor could cause actual result differ materially expressed company verbally well statement made within afternoon press release call webcast live link found website irinoviocom replay made available shortly call concluded turn call inovios president ceo dr jackie shea jackie shea president chief executive officer good afternoon thank everyone joining today call past month transformational inovio today company planning submit first bla second half year preparing potential commercial launch first product approved ino could also become first nonsurgical therapeutic option patient rrp first dna medicine available united state achieve transformation prioritized product pipeline focus promising latestage asset high unmet medical need strong commercial potential remained committed financial discipline cutting operating expense nearly half compared focused leveraging advantage platform deliver promise dna medicine addition significant progress made strategic refocus help drive progress across pipeline including new clinical collaboration supply agreement coherus bioscience develop ino combination loqtorzi throat cancer also shared encouraging result ino ebola booster vaccine continued advance clinicalstage candidate made progress promising preclinical research opportunity nextgeneration candidate adding positive momentum looking ahead several key catalyst help continue momentum across pipeline addition submitting bla fda accelerated approval program plan initiate confirmatory trial second half continue preparation potential launch immunooncology candidate plan finalize trial design evaluation combination loqtorzi patient throat cancer well determine next step glioblastoma deadly form brain cancer also expect key milestone infectious disease candidate including discussion collaborator potential partner around development plan ino ebola booster vaccine first half readout first clinical data phase one trial evaluating antisarscov dmab candidate second half would like pas call cmo mike sumner provide additional detail clinical progress past year goal year aheadmichael sumner chief medical officer thank much jackie greeting everyone jackie outlined made significant progress across pipeline past year thanks strong strategic vision prioritizes promising candidate strong commercial potential one highlight significant progress ino treatment recurrent respiratory papillomatosis rrp familiar rrp devastating rare disease respiratory tract caused hpv characterized wartlike growth called papilloma develop throughout respiratory tract primarily affect larynx vocal cord rrp commonly cause difficulty speaking complete voice loss difficulty swallowing shortness breath choking episode rare case papilloma spread lung become malignant incidence prevalence rpp variable globally depends several factor widely cited yous epidemiology data published estimated active case adult juvenile new case per adult per year way remove papilloma surgery surgery address underlying hpv infection papilloma grow back often forcing patient multiple surgery year worst case could hundred surgery lifetime put extreme physical emotional burden patient including threat permanent vocal cord damage impacting patient ability speak normally ever recent study found even patient le five surgery face chance permanent vocal cord damage patient surgery increase chance conversation patient healthcare provider rrp patient desperate nonsurgical treatment option kim mcclellan president rrp foundation reiterated last week white house forum rare disease even one le surgery year would lifechanging patient slide show real impact ino reducing surgery rrp patient phase trial see majority patient saw reduction surgery treatment needing surgery year treatment reminder counted surgery including surgery performed dosing window believe potential completely change treatment paradigm patient therapeutic adjunct surgery see updated timeline achieved major development regulatory milestone year first quarter shared positive result phase trial later published leading peerreviewed journal read future physician customer base second quarter received orphan drug designation european union followed breakthrough therapy designation fda fourth quarter established path bla submission fda accelerated approval program announced plan earlier year submit bla second half looking forward key catalyst horizon ino include completing submission bla accelerated approval program second half initiating confirmatory trial prior submission requesting rolling submission priority review would lead possible action bla application within six month compared usual month review also target publication immunological data supporting mechanism action second half year finally commercial launch receive fda approval chief commercial officer mark twyman provide update commercial preparation look forward accelerating development promising product candidate next year ultimately delivering promise dna medicine rrp patient across united state shifting gear another latestage dna medicine would like spend time talking ino exciting new clinical collaboration supply agreement coherus bioscience announced earlier year partnership allow u evaluate combination loqtorzi pd inhibitor recently received fda approval treatment nasopharyngeal carcinoma studying combination therapy potential treatment patient locoregionally advanced highrisk hpv positive oropharyngeal squamous cell carcinoma combination therapeutic approach designed leverage antigenspecific cell elicited antitumor immunity generated loqtorzi potentially provide improved patient outcome term agreement coherus provide loqtorzi use planned phase clinical trial provide support regulatory interaction collaboration place submitted clinical development plan fda expect receive feedback second quarter oropharyngeal squamous cell carcinoma type head neck cancer occurs base tongue tonsil andor soft palate commonly referred throat cancer throat cancer typically closely related highrisk subtypes hpv responsible oropharyngeal cancer diagnosed united state also associated tobacco alcohol u hpvpositive throat cancer rapidly increasing incidence among patient highincome country surpassed cervical cancer common hpvrelated cancer diagnosed yous nearly new case year throat cancer patient diagnosed locoregionally advanced disease current treatment practice focused curative option use multitherapeutic approach including surgery chemoradiotherapy treatment protocol patient well measured threeyear progressionfree survival however patient cancer progress face poor clinical outcome proposed trial ino combination loqtorzi patient hpv positive exhibit high risk recurrent disease goal preventing disease progression estimated new patient yous every year deemed meet criterion based previous trial data growing body research indicating dna medicine adept combating hpvrelated disease strong rationale combining proven pd inhibitor result phase trial single agent treatment hpvpositive head neck squamous cell carcinoma patient demonstrated tcell response infiltration cdpositive cell tumor early updated result also published different phase trial combination astrazenecas pdl checkpoint inhibitor durvalumab showing overall response rate comprised four complete response four partial response evaluable patient accompanied increased peripheral hpvspecific cell tumoral cdpositive cell efficacy combination durvalumab resulted median overall survival month compare favorably immune checkpoint blockade therapy alone report median overall survival approximately month combined data set provides compelling evidence support belief potential ino loqtorzi turn call mark provide update commercialization effort ino markmark twyman chief commercial officer thanks mike hello everyone pleased share commercial effort ino well underway continue prepare potential launch still much work done confident commercial launch strategy several important reason first made understanding patient experience top priority every step way continue building understanding market held advisory board panel october last year adult patient suffering rrp shared journey diagnosis treatment provided invaluable insight unmet need rrp patient community large also conducted advisory board healthcare provider specializing treatment rrp caregiver juvenile patient next understand mapping physician landscape critical commercial success end initiated comprehensive market analysis physician treat rrp allow u focus field allow u focus field deployment make smart investment decision also experienced commercial team wellversed every aspect commercialization process innovative product particularly rare disease collective expertise putting plan essential system place successful launch essential progress thus far help ensure stay track moving forward perhaps importantly believe ino offer potential compelling clinical commercial advantage serve important foundation commercial effort see fda advised use data completed phase trial submit bla accelerated approval program trial ino immunogenic generally well tolerated patient across disease severity continuum reduction number surgery compared previous year data key supporting application subsequent receipt breakthrough therapy designation fda commercial standpoint ino offer several key differentiator target shown similar efficacy across hpv hpv rrp patient trial range two eight surgery prior year efficacy demonstrated across range disease severity ino also offer important attribute typical dna medicine platform including potential redosing stability three year refrigerator temperature administration cellectra proprietary electroporation device well tolerated patient easy use healthcare provider phase trial consistent use trial also important commercialization ino welldefined commercial scale manufacturing process well orphan drug orphan drug designation yous eu offer potential commercial incentive regulatory mechanism market turn call back ceo jackie shea additional pipeline update jackiejackie shea president chief executive officer thank mark mark highlighted important progress made ino ino focusing majority internal resource advancing candidate however several latestage clinicalstage asset nextgeneration candidate plan advance partnership collaboration across industry academia governmental agency would like provide brief update earlier mentioned encouraging result announced early phase b clinical trial ebola vaccine booster candidate recently received feedback fda identified potential development pathway discussion collaborator potential partner define next step ino two current disease target glioblastoma discussion partner regeneron investigator next step goal finalized plan first half second target prevent cancer reoccurrence cancer adult cancer noncancer patient brca mutation phase b study conducted university pennsylvania look forward update become available partner apollobio also conducting phase trial vgx therapeutic treatment cervical hsil caused hpv phase trial sponsored aid malignancy consortium also underway evaluating vgx hivpositive participant anal hsil caused hpv also exciting work advancing nextgeneration dna medicine technology including trial collaborator wistar institute evaluating dnalaunched nanoparticles dlnps dlnps designed provide high maintained level antibody response including neutralizing antibody continuing generate cell response first dlnp enter clinical trial ino preventative hiv vaccine candidate phase trial sponsored funded niaid finally wistar partner astrazeneca university pennsylvania indiana university leading phase trial using dnaencoded monoclonal antibody dmab technology develop dmabs therapeutic preventative treatment covid excited future hold innovative technology look forward sharing year ahead turn call cfo peter ky fourthquarter fullyear financial summary peterpeter ky chief financial officer thank jackie today would like provide overview inovios operational highlight financial condition fourth quarter full year jackie mike mark noted made significant progress across pipeline past year advancing key candidate working successfully reduce operational spend pipeline reprioritization see slide reduced total operating spend dropping million fourth quarter million fourth quarter decrease fullyear operating expense also nearly cut half million million breaking operating expense bit rd expense fourth quarter totaled million compared million period fullyear rd expense million compared million period year decrease yearoveryear decrease rd expense primarily result lower drug manufacturing clinical trial expense outside service expense inventory related ino covid study lower employee consulting compensation including stockbased compensation among variance ga expense fourthquarter million compared million period ga expense full year million compared million period revenue fourth quarter compared period revenue full year compared million period note revenue reported associated procurement contract yous department defense inovios device accessory used delivery ino covid vaccine candidate since discontinued factor combine bring net loss fourth quarter million per share basic diluted net loss fullyear million per share basic diluted finished fourth quarter million cash cash equivalent shortterm investment compared million december st inovio estimate cash runway extend second quarter projection includes operational net cash burn estimate approximately million first quarter amount excludes repayment million remaining principal accrued interest convertible senior note matured march st including repayment total net cash burn first quarter expected approximately million cash runway projection include fund may raised aftermarket program capitalraise activity reminder find full financial statement afternoon press release well form k filed sec turn back jackiejackie shea president chief executive officer thanks peter would like open call answer question might operator question answer operatorthank lady gentleman begin questionandanswer session operator instruction first question come line hartaj singh oppenheimer company please go aheadhartaj singh oppenheimer company analyst oh great thank thanks question couple actually mind one know confirmatory trial discussion fda little bit fact believe going start sometime last year early year know fda kind grant accelerated approval process maybe give u color look like especially long would take recruit know evaluation period roughly could read looking guidance secondly know talked lot kols know know therapy rrp think broadly apply lot patient academic know literature suggests know cost surgery per patient per year add time thinking pricing comp color thought thanks questionsjackie shea president chief executive officer good afternoon hartaj great question think covered call btd multidisciplinary meeting held fda christmas got guidance number different element needed go bla submission part getting guidance design confirmatory trial going hand mike provide bit detail perhaps mark talk comparators thought pricing mikemichael sumner chief medical officer yeah thanks jackie hi hartaj respect confirmatory trial think final stage discussing detail agency hoping soon position reveal sort detail around design future strategy also asked sort recruitment readout know get final sample size difficult totally predict long going take know say know included eight clinical trial site original phase study certainly going go broader confirmatory study think know talked consistently patient need openness receive treatment nonsurgical option really hoping able recruit subject pretty quickly respect readout really going depend final final design sort length observation going need include hopefully next quarterly call able provide color around thatjackie shea president chief executive officer thanks mike mark pricing parametersmark twyman chief commercial officer yes hey hartaj good good talk think said previously know rrp rare disease would anticipate know rare disease pricing asset think said though number rare disease analog also positioned alternative surgery assessing part pricing work would say get closer launch better position say thathartaj singh oppenheimer company analyst ok go quick followup mean publishing pharmacoeconomic data also get closer launching maybe thanks questionsmark twyman chief commercial officer think going direct question mike mike would like respond thatmichael sumner chief medical officer yeah certainly mean obviously include many quality life impact patient phase study mean certainly process assessing document impact know rrp patient likely include measure prospectively confirmatory study mean obviously aim supporting evidence price eventually sethartaj singh oppenheimer company analyst ok thank alloperatorquestion come line roy buchanan citizen please go aheadroy buchanan jmp security analyst hey great guess maybe sticking second others say commercialscale manufacturing many patient think address think address entire population thinking initial penetrationjackie shea president chief executive officer yeah mark want take onemark twyman chief commercial officer sure take whack additional comment feel free add guess way respond question know would expect done sort know lot modeling working sort closely manufacturing team sort confident sort know based market projection estimate around know adoption etc etc able sort fully meet demand jackie shea president chief executive officer yeah add manufacturing side know already got two commercial scale product candidate know rare disease term dose requirement actual number dose requirement manageable u manufacturing standpoint think pretty well positioned manufacturing standpoint able build launch inventory able support market need first couple year pretty easilyroy buchanan jmp security analyst ok perfect switching pipeline deeper pipeline bit guess anything could tell u design submitted phase expect registrational last slide deck know eight additional clinicalstage candidate help u understand bit guess level development candidate given runway q guess runway assume term develop pipeline beyond thanksjackie shea president chief executive officer yeah great mike take phase design thinking talk rest pipeline candidatemichael sumner chief medical officer yeah thank mean heard call today clearly sort articulated patient population going know highrisk patient locoregionally advanced disease high risk really come based tumor size local infiltration local node involvement also smoking history think lot work kols global basis define population mean think developing candidate mean based wellknown safety profile pd inhibitor also welldocumented safety profile dna medicine certainly feel registration study obviously ultimately decided agency know looked design followed sort traditional way mean obviously agency going want understand contribution component clearly element design submitted agency really waiting discussion quarter determine actual pathway forward really look likejackie shea president chief executive officer thanks mike talk rest pipeline mentioned call clearly focusing majority internal resource advancing toward license launch hopefully next year moving forward number partnership place asset pipeline going leveraging partnership nondilutive funding mechanism grant etc able help move candidate forward earlierstage work particularly preclinical work also move forward think way leveraging partnership nondilutive funding mechanism moving candidate forward generate meaningful progress wellroy buchanan jmp security analyst ok thanks taking questionsoperatoryour next question come line gregory renza rbc capital market please go aheadanish nikhanj rbc capital market analyst hi guy anish greg thanks taking question couple firstly rrp thinking thinking ahead market shaping pushback gotten date engaging kols getting patient onto therapy like versus standardofcare surgery feedback built awareness education directive secondly question could walk u collaboration coherus came selection loqtorzi combination candidate among potential candidate best leverage partnership going forward thanks jackie shea president chief executive officer yeah thanks anish really great candidate going ask mark comment thinking – mike maybe would like comment clinical aspect theremark twyman chief commercial officer yeah thanks jackie guess first thing would say commercial perspective never excited launching new product think speaks specifically going address question know conducted know multiple advisory board hcps treating rrp well sort patient know closely aligned know listening rrp foundation suggests important know probably last know three four year one thing heard physician like surgery right looking alternative surgery mike know alluded mean surgery address underlying infection right cycle know surgical procedure surgical procedure actually surgery driving morbidity looking option right sort unlike know launch replacing surgical alternative physician welcoming right disincentive use ino current standard care wholly inadequate similarly patient perspective mike mentioned devastating disease even reduction sort one surgery year lifechanging really really confident everything learned marketplace portends know going really successful launch jackie shea president chief executive officer thanks mark mike want talk clinical aspect know need patient physician highlightingmichael sumner chief medical officer yeah absolutely mean heard talk today mean latest data published simon best john hopkins around ability cause permanent vocal cord damage really mind sort rrp surgeon spoken recognize know surgery hugely beneficial patient know understand sooner later going damage caused surgical perspective mark said know really would excited patient think know looking nonsurgical treatment patient know keep know going back sort discussion kim mcclellan know really know every surgery impact patient life know saw graph showed earlier tremendous impact reducing surgical burden rrp population really feel know see clinical efficacy associate safety data accomplished know accumulated date really reason heard patient would want nonsurgical option excited move program forwardmark twyman chief commercial officer hey mike add one point real quick one sort really important dimension patient component market unlike rare disease genzyme case spend lot effort identifying patient right getting originate therapy mean case rrp mean patient originate treatment primary primary reason impact voice quality right know combination patient originate treatment rrp fact surgery inadequate burden cause lot morbidity physician looking alternative really put u good position jackie shea president chief executive officer yeah think excellent point mark moving think maybe take step back saw really encouraging data monotherapy combination durvalumab know disappointed astrazeneca decided move durvalumab forward head neck space excited saw study really go back one strength platform ability generate antigenspecific cytotoxic cd cell know capable getting tumor know hpv dysplasia program capable clearing hpv precancerous lesion leading viral clearance wanted move forward saw lot promise really conducted quite extensive analysis looking right pd use combination mike maybe now point might want jump talk reason excited loqtorzimichael sumner chief medical officer absolutely mean conducting clinical partnership mean first finding partner excited program fact loqtorzi know work lot kols hopefully eventually prescribe know give unique insight seeing value see loqtorzi know partner great work share enthusiasm program recent approval nasopharyngeal carcinoma think know want also see use loqtorzi expand know far know everything every interaction coherus know positive bring know knowledge head neck space table well really know encouraged continue partnership perform clinical trialanish nikhanj rbc capital market analyst thanks guy operatoryour next question come line roger song jefferies please go aheadunknown speaker hey good afternoon leon chung roger thank taking question guess u regarding confirmatory study could comment know thinking turnover care practice among different site see impact study result know point powering assumption thinking confirmatory study thank youjackie shea president chief executive officer yeah mike take onemichael sumner chief medical officer yeah absolutely thanks roger know yet obviously talk samplesize element certainly address clinical trial site element mean phase study actually eight recruiting site know result subject phase study analysis certainly sitetosite variation believe result consistent look utilize site confirmatory study certainly concern u obviously look site using ipsp device lot experience previous phase program know concern usjackie shea president chief executive officer mike maybe add add know addition working eight site also enroll patient across disease spectrum also enroll patient hpv hpv think know phase study built good understanding variability within patient populationmichael sumner chief medical officer absolutelyunknown speaker thank maybe another question may regarding phase data know know one key difference precision study included subject right know including treatment window maybe could remind u see know include surgery treatment windowjackie shea president chief executive officer yeah great question mean designed trial every surgery matter patient know heard time time patient every surgery matter mike want talk data sure disclosed yet publishedmichael sumner chief medical officer provided detail think also going liketolike comparison would obviously want include full week excluding surgery surgical window mean looking collecting data going available short termunknown speaker got thank usoperatoroperator instruction next question come line yi chen hc wainwright please go aheadyi chen hc wainwright company analyst thank taking question could comment typical age range rrp patient percentage patient population actually medicare much time think would take secure medicare reimbursement following potential fda approval thank youjackie shea president chief executive officer yeah great question mike want talk age range mark maybe take medicare questionmichael sumner chief medical officer yeah absolutely rrp involves age age group actually sort three peak instance first one pediatric peak usually around sort five sevenyearold mark earlieradult peak obviously follows sexual activity onset usually around age also developed lateronset peak usually around age really encompasses age group vast majority still actually vast majority majority still around age group elderly population growing rapidlymark twyman chief commercial officer hi mark thanks thanks question really good question think said earlier comment sort focus precision know going key success consistent particularly pertains kind mix patient private versus versus medicare medicaid going get lot additional information work mentioned earlier going assessing sort physician landscape analysis start patient level able sort identify claim adjudicated whether adjudicated private sector medicare medicaid really kind help u know focus effort commercial payer important also help u understand know approach need perspective medicare medicaid know really kind three pillar focusing commercial launch distribution market access piece well field deployment moving fast give know specific timeline say started early objective making sure patient private medicare medicaid access ino quickly possibleyi chen hc wainwright company analyst thank could comment regulatory pathway going forward european unionjackie shea president chief executive officer mikemichael sumner chief medical officer yeah obviously engaged european union yet disclosed strategy going europe certainly believe pathway forward based information received think able give detail upcoming callsyi chen hc wainwright company analyst ok thank youjackie shea president chief executive officer yeah add mike answer though know rrp unfortunately like hpv everywhere strong unmet medical need well europe standard care may differ slightly yous also important consideration take account certainly trying provide detail discussion european regulator progressyi chen hc wainwright company analyst ok thank youoperatorladies gentleman question time turn call back jackie shea president ceo closing remark please go aheadjackie shea president chief executive officer thank opened call highlighting transformation inovio undergone last year transformation made possible renewed strategic focus strength dna medicine platform aim become commercialstage company made progress built foundation longterm success continue build advanced dna medicine patient around world could potentially benefit promise look forward sharing update progress year ahead thank attention great evening everyoneoperatoroperator signoff duration minutescall participantsthomas hong investor relation managerjackie shea president chief executive officermichael sumner chief medical officermark twyman chief commercial officerpeter ky chief financial officerhartaj singh oppenheimer company analystroy buchanan jmp security analystanish nikhanj rbc capital market analystunknown speakeryi chen hc wainwright company analyst ino analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy